MetaboParis-Santé platform first in France to install Bruker In Vitro Diagnostic research by NMR* system

by Christina Smith Contributor

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or
Contributors are fully responsible for assuring they own any required copyright for any content they submit to This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   260    Comments 0

PARIS, France: Université de Paris has installed new Bruker In Vitro Diagnostic research

(IVDr) nuclear magnetic resonance (NMR) spectrometer within its MetaboParis-Santé

platform located in the center of Paris city, France. One of the most prestigious universities

in France, known for its cutting-edge research in medicine and more broadly biology and

health, is the first facility in the country to benefit from a IVDr instrument of its kind.

MetaboParis-Santé is upheld as a national center of excellence for the metabolic analysis by

NMR of human biofluids.

Thanks to the Bruker IVDr technology, Université de Paris can now analyze human samples,

such as plasma, serum, or urine, to automatically obtain their composition and identify the

main metabolites present, more than one hundred parameters, all in less than 15 minutes.

The new IVDr system is an asset in supporting the diagnosis of conditions that present a

major public health issue: “Blood analyses will, for example, make it possible to make a

better assessment of cancer such as lymphoma by establishing a more detailed lipid profile

than that provided by conventional biological analysis methods,” explains Dr. Gildas Bertho,

Scientific Director of the MetaboParis-Santé platform. He continues: “Our work with

academic, industrial, and medical laboratories is what makes us so unique, and we

recognize the role of Bruker in supporting these collaborations.”


Claire Cannet, Market Manager for Clinical RTD at Bruker BioSpin: "Bruker is proud to

support the NMR community further and drive advanced research in the clinical research

field. The MetaboParis-Santé platform represents a huge step for innovative disease

analysis and, through its partnerships, together we are furthering knowledge into molecular

phenomics questions."


The MetaboParis-Santé project has established partnerships with Assistance Publique–

Hôpitaux de Paris (AP-HP) and other hospitals throughout France to use and promote NMR

technology, leading the way in research. It benefits from a national network of scientific

collaborations supported by the Île-de-France region, the French National Centre for

Scientific Research (CNRS) and the French National Institute of Health and Medical

Research (Inserm), and, at present, is engaged in two major national cohort studies in the

fight against cancer and COVID-19. Now that NMR has been established as a crucialtechnique within the MetaboParis-Santé project, it is the first step to revolutionize routine biological analysis in French laboratories.


About MetaboParis-Santé

MetaboParis-Santé is a metabolomic platform located in the NMR department (Dir G.

Bertho) of UMR8601 CNRS and administered by the UMS BioMedTech Facilities - Inserm

US36 | CNRS UMS2009 | Université de Paris. It deals with requests for biological analyzes

from the private and public sectors, mainly for metabolomics studies. This platform relies on

the spectroscopic expertise developed in the NMR of Biological Substances research team

(Dir N. Giraud) working with complex sample analysis strategies in the context of scientific

collaborations. This IVDr equipment, improved protocols, and the strong expertise of the

NMR staff in metabolomics brings together a large range of key players from academic,

industrial, and medical laboratories from hospitals. For more information, please visit:


About Université de Paris

Université de Paris is one of the leading research-intensive universities in France (4th in the

ARWU ranking, 1st in the Leiden ranking for the 1% of the most cited publications). Across a

broad range of disciplines that include health sciences, formal and experimental sciences

and the humanities and social sciences, Université de Paris builds on the highest quality

disciplinary research to cultivate multi and interdisciplinary collaborations in research and

education. Université de Paris is composed of three Faculties (Health, Sciences and

Humanities and Social sciences), a component institution, the Paris Institute of Earth

Physics, (IPGP) and now a partner research organization, the Institut Pasteur. Université de

Paris has 63,000 students, 7,500 teacher-researchers and researchers, 21 doctoral schools

and 119 research units.


About Bruker Corporation

Bruker is enabling scientists to make breakthrough discoveries and develop new

applications that improve the quality of human life. Bruker’s high performance scientific

instruments and high value analytical and diagnostic solutions enable scientists to explore

life and materials at molecular, cellular, and microscopic levels. In close cooperation with our

customers, Bruker is enabling innovation, improved productivity, and customer success in

life science molecular and cell biology research, in applied and pharma applications, in

microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinica limaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit:


* Bruker NMR is for Research Use Only and not for use in Clinical Diagnostic Procedures Customer


Contact: Media Contact (Bruker):

Thorsten Thiel

VP of Group Marketing

Bruker BioSpin Group


Claire Cannet

Bruker BioSpin Group

Market Manager Clinical RTD

Subscribe to Newsletter
Share this:              


There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *